drugset / Trial / NCT07530549
A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy
Phase 2
Not yet recruiting
40 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing Chest Hospital, Capital Medical University · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe First Affiliated Hospital with Nanjing Medical University · collabThe Luhe Teaching Hospital of the Capital Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is Iparomlimab and tuvonralimab (QL1706) combined with chemoradiotherapy in the treatment of locally advanced esophageal cancer after failed neoadjuvant chemoimmunotherapy. The main question it aims to answer is： Can it bring survival benefits and safet to patients？Subsequent evaluation will determine whether the patient undergoes surgical treatment. Follow-up will be conducted to assess the efficacy and safety of the treatment。
Timeline
- Start
- 2026-04-01
- Primary completion
- 2027-12-31
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | — |
| Background | S-1 | Small molecule | 40 mg/m2 | — |
| Background | S-1 | Small molecule | 60 mg/m2 | — |